Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stage III trial of subcutaneous versus intravenous rituximab with CHOP or CVP in previously untreated follicular lymphoma, followed by maintenance
2010-021377-36Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Roche. Primary endpoint: Stage 1 primary variable. Started Sep 2010; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2010-021377-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021377-36.